Ewing Sarcoma Clinical Trials in Philadelphia, Pennsylvania

6 studies are recruiting for ewing sarcoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

   This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

   Stage

   Phase 1

   Ages

   12 to 85

   Site

   Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania

   Locations

   37 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT03715933 on ClinicalTrials.gov

3. Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

   The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.

   Stage

   Phase 1

   Ages

   5 to 40

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   4 in total

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT06156410 on ClinicalTrials.gov

4. Lurbinectedin in FET-Fused Tumors

   The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

   Stage

   Phase 1

   Ages

   10 and older

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT05918640 on ClinicalTrials.gov

5. Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

   The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

   Stage

   Phase 1

   Ages

   2 and older

   Site

   Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT07297979 on ClinicalTrials.gov

6. Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

   This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the …

   Stage

   Phase 1

   Ages

   2 to 30

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   15 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05734066 on ClinicalTrials.gov